No Data
No Data
ETFs Surged Past $500 Billion Last Year as Canada Firms Rode U.S. Stock Rally
Wells Fargo Maintains Pfizer Inc(PFE.CA) With Hold Rating, Maintains Target Price $28
Wells Fargo analyst Mohit Bansal maintains $Pfizer Inc(PFE.CA)$ with a hold rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 63.9% and a
Goldman Sachs Maintains Pfizer Inc(PFE.CA) With Buy Rating, Maintains Target Price $31
Goldman Sachs analyst Chris Shibutani maintains $Pfizer Inc(PFE.CA)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 44.9% and
UBS Maintains Pfizer Inc(PFE.CA) With Hold Rating, Raises Target Price to $30
UBS analyst Trung Huynh maintains $Pfizer Inc(PFE.CA)$ with a hold rating, and adjusts the target price from $28 to $30.According to TipRanks data, the analyst has a success rate of 75.5% and a
Truist Financial Maintains Pfizer Inc(PFE.CA) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Pfizer Inc(PFE.CA)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 51.5% and a total average return of 4.6%
A Quick Look at Today's Ratings for Pfizer Inc(PFE.CA), With a Forecast Between $28 to $35
On Jul 12, major Wall Street analysts update their ratings for $Pfizer Inc(PFE.CA)$, with price targets ranging from $28 to $35.Morgan Stanley analyst Terence Flynn maintains with a hold rating, and